[ad_1]
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /CNW/ — Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) introduced right now the current train of Onward Therapeutics’ second of three instalments of fairness funding in Emercell. With this funding, Onward Therapeutics has turn out to be Emercell’s majority shareholder.
Emercell has developed a platform expertise to supply off-the-shelf pure killer (NK) cells. NK cells are extremely potent immune effectors, used alone as a monotherapy, or together with therapeutic antibodies, or are genetically engineered to supply Chimeric Antigen Receptor (CAR)-NK cells for the remedy of hematological malignancies and stable tumors. NK-001 is an optimized cell remedy product consisting of extremely activated and alloreactive allogeneic NK cells. Its patented manufacturing course of permits full industrialization utilizing the identical batch of NK cells for a number of sufferers.
“This second fairness funding in Emercell confirms that the NK-001 mission has been advancing nicely since our first fairness funding in February 2021, and we will scale up and industrialize the manufacturing of activated NK cells quickly, to supply new therapies for most cancers sufferers,” mentioned Dr. C. Grace Yeh, Chairman and CEO of Onward Therapeutics.
“We’re happy that the collaboration with Onward Therapeutics has reached one other vital milestone. Their funding permits us to pursue the NK-001 mission and give attention to the manufacturing of scientific batches,” declared Dr. Patrick Henno, Founder and CEO of Emercell. “We will additionally begin additional optimizing our manufacturing course of for NK cells and exploring different potential new cell therapies,” commented Dr. Alain Herrera, Chairman of the board of Emercell.
About Onward Therapeutics
Onward Therapeutics is an oncology firm specializing in the identification and growth of revolutionary medicines for the remedy of most cancers. The Firm, led by an skilled workforce in translational science and drug growth, acquires licenses for potential growth candidates and invests in companions with transformative expertise platforms. Onward Therapeutics licensed a preclinical stage bispecific antibody (OT-A201) focusing on two immune checkpoints from Biomunex Prescription drugs SAS, Paris, France; has an unique choice to a worldwide license settlement for an onco-metabolism program with Institut du Most cancers de Montpellier (ICM); and collaborates with Emercell SAS, Montpellier, France, within the growth of NK-001, allogenic pure killer cells. As well as, the Firm invested in Biomunex Prescription drugs SAS for his or her multi-specific antibody platform, and in Emercell SAS for his or her NK cell expertise. The corporate is headquartered at Biopôle (a life sciences campus in Epalinges), close to Lausanne, Switzerland, has an affiliate in Paris, France, and an workplace in Taipei, Taiwan.
About Emercell
Emercell is an oncology firm growing a platform expertise to supply off-the-shelf allogenic pure killer (NK) cells. The corporate’s R&D actions are situated on the IRMB (Institute of Regenerative Medication and Biotherapies) on the Saint-Éloi College Hospital Middle, Montpellier, France. Emercell’s lead drug candidate, NK-001, is meant, amongst others, for the remedy of lymphoma sufferers who’re refractory to standard therapies. It’s a patented course of for pre-activating and amplifying allogeneic NK (Pure Killer) cells. Emercell collaborates with quite a few industrial and educational companions. The corporate has obtained the help of the Occitanie Area (ADI) and Bpifrance and has obtained a FUI (financing). Emercell is a member of Eurobiomed.
SOURCE Onward Therapeutics SA; Emercell SAS
For additional data: Media and Investor Contacts, Onward Therapeutics, Dr. C. Grace Yeh, Chairman & CEO, [email protected], (+886)-988-347-457; Emercell, Dr. Patrick Henno, President, [email protected], (+33)-6-14-77-39-21
[ad_2]
Supply hyperlink